

Applicant Docket No.: PG 4113 USw
U.S. Serial No. 09/971,799
Page 14 of 15

pyridinyl)ethoxy)hexyl)-amino)methyl}benzenemethanol, flunisolide, tiredane, triamcinalone, isoprenaline, metaproterenol, perbuterol, peproterol, rimiterol, ephedrine, fenoterol, formoterol, atropine, oxitropium, acetonide, phenylephrine, phenylpropanolamine, terbutaline, isoetharine, tulobuterol, orciprenaline, salts, esters and solvates thereof, and combinations thereof.

124. (Currently Amended) The drug product of claim 106 wherein the medicament is a member selected from the group consisting of fluticasone, beclomethasone, salmeterol, albuterol, budesonide, ~~salbutamol~~, ipratropium, salts, esters and solvates thereof, and combinations thereof.

a

125. A drug product comprising:
a means for dispensing metered amounts of fluid material from a means for reserving the fluid material;
a drug formulation located within said dispensing means comprising a pharmaceutically acceptable medicament and propellant; and
a flexible packaging means for overwrapping and sealing said dispensing means,
wherein said flexible packaging means is impermeable to water vapor and permeable to said propellant,
and wherein said flexible packaging means substantially prevents ingress of water vapor and particulate matter and permits egression of said propellant.

REMARKS

i. Response to Election of Species Requirement

Applicants hereby elect the species set forth in category (f) of the Office Action, i.e., the drug in the drug formulation being albuterol sulphate. It is believed that the following claims are readable on this elected species: 1, 3, 11-81, 89-116, and 124-125. This election is made without traverse in that Applicant believes that the species are patentably distinct.

Applicant Docket No.: PG 4113 USw
U.S. Serial No. 09/971,799
Page 15 of 15

ii. Amendments

Claims 3, 11, 89, and 124 have been amended to consistently recite albuterol being employed as one possible drug. In particular, Claims 3, 89, and 124 all previously recited both albuterol and salbutamol in a Markush group. Such an amendment is not made in view of the prior art, and is set forth to merely clarify the claimed subject matter.

Examination on the merits is respectfully requested.

Respectfully submitted,

Date:

April 9, 2003



Robert J. Smith
Reg. No. 40,820
Attorney for Applicants

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709-3398
Direct Phone (919)483-9616
Facsimile (919)483-7988



23347

PATENT TRADEMARK OFFICE